


SELECTED CLINICAL RESEARCH PROTOCOLS FOR UROLOGIC CANCERS



Diagnostic

E-8897 Diagnostic Study to Correlate Histopathology, Immunohistochemistry, and Quantitative Radiology With Outcome in Patients With Early Stage Nonseminomatous Germ Cell Tumor of the Testis

Chairperson: Richard S. Foster. Telephone: 317-274-3458. Lead organization: Eastern Cooperative Oncology Group. Age range: 15 and over.

Prevention

MDA-ID-99368, NCI-P00-0165 Phase IIB/III Randomized Chemoprevention Study of Celecoxib in Patients With Superficial Transitional Cell Carcinoma of the Bladder at High Risk for Recurrence

Chairperson: Anita L. Sabichi. Telephone: 713-745-4928. Lead organization: University of Texas - MD Anderson Cancer Center. Age range: 18 and over.

Phase II

NCI-G00-1831, UCCRC-9193, UCCRC-CTRC-9806 Phase II Study of Adjuvant Gemcitabine, Cisplatin, and Amifostine in Patients With Completely Resected Locally Advanced Bladder Cancer

Chairperson: Walter M. Stadler. Telephone: 773-702-4150. Lead organization: University of Chicago Cancer Research Center. Age range: 18 and over.

MSKCC-95031, NCI-V95-0743 Phase II Study of Cisplatin, Ifosfamide, and Paclitaxel in Patients With Unresectable or Metastatic Urothelial Tumors

Chairperson: Dean F. Bajorin. Telephone: 212-639-6708. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

SWOG-S0028 Phase II Study of Gemcitabine and Paclitaxel in Patients With Advanced or Recurrent Urothelial Cancer

Chairperson: Derek Raghavan. Telephone: 323-865-3962. Lead organization: Southwest Oncology Group. Age range: 70 and over or under 60.

E-5899 Phase II Study of Paclitaxel and Gemcitabine in Patients With Advanced Transitional Cell Carcinoma of the Urothelium With Renal Insufficiency

Chairperson: David J. Vaughn. Telephone: 215-349-8140. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

SWOG-S0031 Phase II Study of ZD 1839 in Patients With Advanced Transitional Cell Carcinoma of the Urothelium

Chairperson: Daniel P. Petrylak. Telephone: 212-305-1731. Lead organization: Southwest Oncology Group. Age range: any age.

NCI-95-C-0154, NCI-T94-0134N Phase II Pilot Study of Human Papilloma Virus 16 (HPV16) E6 and E7 Peptide Vaccines in Patients With Advanced or Recurrent Carcinoma of the Cervix or Other Tumors Carrying HPV16

Chairperson: Samir N. Khleif. Telephone: 301-435-5392. Lead organization: Center for Cancer Research. Age range: over 18.

Phase I

CRC-PHASE I/II-PH1/073, NCI-954 Phase I Study of Intravesicular Suramin in Patients With Recurrent Superficial Bladder Cancer

Chairperson: Adrian L. Harris. Telephone: 01865-226184. Lead organization: Cancer Research Campaign Clinical Trials Unit-London. Age range: 18 and over.

This list of clinical research protocols relating to urologic cancers is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at http://www.cancer.gov/clinical_trials.

A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.